Varenicline Treatment of Alcohol Dependence in Smokers

This study is currently recruiting participants.
Verified October 2012 by Yale University
Sponsor:
Collaborator:
Columbia University
Information provided by (Responsible Party):
Stephanie O'Malley, Yale University
ClinicalTrials.gov Identifier:
NCT01553136
First received: February 16, 2012
Last updated: October 11, 2012
Last verified: October 2012
  Purpose

The purpose of this study is to determine whether varenicline is effective in the treatment of alcohol dependence in smokers.


Condition Intervention Phase
Alcoholism
Alcohol Abuse
Smoking
Alcohol Drinking
Drug: Varenicline
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: 1/2-Multi-site Study: Varenicline Treatment of Alcohol Dependent Smokers

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Percentage of heavy drinking days during the last 8 weeks of treatment [ Time Frame: week 11 ] [ Designated as safety issue: No ]
    The percentage of days of heavy drinking will be examined over the final 8 weeks of the study averaged by month (weeks 9-12 and weeks 13-16). A heavy drinking day is defined as 5 or more standard drinks for men and 4 or more standard drinks for women. A standard drink contains approximately 0.6 fluid ounces of pure alcohol.

  • Percentage of heavy drinking days during the last 8 weeks of treatment [ Time Frame: week 13 ] [ Designated as safety issue: No ]
    The percentage of days of heavy drinking will be examined over the final 8 weeks of the study averaged by month (weeks 9-12 and weeks 13-16). A heavy drinking day is defined as 5 or more standard drinks for men and 4 or more standard drinks for women. A standard drink contains approximately 0.6 fluid ounces of pure alcohol.

  • Percentage of heavy drinking days during the last 8 weeks of treatment [ Time Frame: Week 15 ] [ Designated as safety issue: No ]
    The percentage of days of heavy drinking will be examined over the final 8 weeks of the study averaged by month (weeks 9-12 and weeks 13-16). A heavy drinking day is defined as 5 or more standard drinks for men and 4 or more standard drinks for women. A standard drink contains approximately 0.6 fluid ounces of pure alcohol.

  • Percentage of heavy drinking days during the last 8 weeks of treatment [ Time Frame: Week 17 ] [ Designated as safety issue: No ]
    The percentage of days of heavy drinking will be examined over the final 8 weeks of the study averaged by month (weeks 9-12 and weeks 13-16). A heavy drinking day is defined as 5 or more standard drinks for men and 4 or more standard drinks for women. A standard drink contains approximately 0.6 fluid ounces of pure alcohol.


Secondary Outcome Measures:
  • Smoking abstinence [ Time Frame: abstinence over the last month of treatment is based on data obtained at weeks 15 and 17 ] [ Designated as safety issue: No ]
    Smoking abstinence is defined by self-reported abstinence from smoking for the last four weeks of treatment (weeks 13-16) and a urine cotinine level less than 15ng/mL measured at week 17.

  • Drinking related consequences [ Time Frame: End of treatment (Week 17) ] [ Designated as safety issue: No ]
    A self-report measure of negative consequences from drinking will be administered and the total score will be analyzed.


Estimated Enrollment: 160
Study Start Date: September 2012
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Sugar pill Drug: Varenicline
0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
Other Name: Chantix
Active Comparator: Varenicline Drug: Varenicline
0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
Other Name: Chantix

Detailed Description:

Building upon knowledge about the role of nicotinic acetylcholine receptors in alcohol drinking and smoking, varenicline, a smoking cessation treatment that targets these receptors, will be tested as a potential treatment for alcohol dependent smokers seeking alcohol treatment.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • are 18 - 70 years of age and seeking treatment of alcohol drinking;
  • meet DSM-IV TR Criteria for Alcohol Dependence
  • smoke ≥ 5 cigarettes/day for ≥ 6 months and have a CO > 10ppm;
  • report heavy drinking on at least 2 days on average per week (i.e., ≥ 4 drinks on an occasion for women and ≥ 5 drinks for men) for the past 90 days and no more than 7 consecutive days of abstinence at intake.

Exclusion Criteria:

  • exhibit current, clinically significant physical disease or abnormality based on medical history, physical examination, or routine laboratory evaluation including:

    • any unexplained elevations in liver enzymes (i.e., transaminases, bilirubin)
    • clinically significant, unstable cardiovascular disease/uncontrolled hypertension
    • hepatic or renal impairment
    • severe obstructive pulmonary disease
    • diabetes mellitus requiring insulin or certain oral medications (i.e., sulfonylureas) and an A1C hemoglobin test score of > 7 for participants not prescribed these medications
    • baseline systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 95 mm Hg
  • have a history of cancer (except treated basal cell or squamous cell carcinoma of the skin)
  • have a history of clinically significant allergic reactions
  • exhibit serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe major depression, panic disorder, borderline personality disorder, organic mood or mental disorders by history or psychological examination
  • report current suicidal ideation (past 6 months) or lifetime hx of suicidal behavior assessed with the Columbia Suicide Severity Rating Scale 60; or risk for aggression using a cut-off of 15 or more on the Overt Aggression Scale - Modified Aggression Scale or 6 or more on the OAS-M Irritability Subscale 61.
  • have used any psychotropic drug in the past month, except individuals who are on a stable dose of a Selective Serotonin Reuptake Inhibitor for at least two months
  • have a current DSM-IV diagnosis of drug dependence other than nicotine or alcohol
  • are at risk for an alcohol withdrawal syndrome as evidenced by:

    • a history of seizures, delirium, or hallucinations during alcohol withdrawal
    • a Clinical Institute Withdrawal Assessment scale 62 score of > 8,
    • report drinking to avoid withdrawal symptoms
    • have required medical treatment of alcohol withdrawal within the past 6 months
  • have used another investigational drug within 30 days or have used medications to treat alcohol (e.g., naltrexone, topiramate, acamprosate, disulfiram) or nicotine use (e.g., clonidine, varenicline, bupropion, nicotine replacement) in the past 3 months or intend to use these medications;prior use of nicotine replacement in situations where smoking is not permitted (e.g., planes) without the intention to quit smoking is not exclusionary;
  • intend to donate blood or blood products during the treatment phase of the study
  • have a Body Mass Index (calculated as weight in kilograms divided by the square of height in meters) less than 15 or greater than 38 or weight less than 45 kg
  • are a female of childbearing potential who is pregnant, nursing, or not practicing effective contraception (oral, injectable, or implantable contraceptives, intrauterine device, or barrier method with spermicide).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01553136

Locations
United States, Connecticut
Connecticut Mental Health Center - Substance Abuse Treatment Unit Recruiting
New Haven, Connecticut, United States, 06511
Contact: Susan Neveu     203-974-7588     susan.neveu@yale.edu    
Contact: Corey Roos     203-974-5763     corey.roos@yale.edu    
Principal Investigator: Stephanie O'Malley, PhD            
United States, New York
Parallax Center Recruiting
New York, New York, United States, 10016
Contact: Mitch Greene     212-779-9207     mgreene@parallaxcenter.com    
Principal Investigator: Allen Zweben, PhD            
Sponsors and Collaborators
Yale University
Columbia University
Investigators
Principal Investigator: Stephanie O'Malley, PhD Yale University
Principal Investigator: Allen Zweben, PhD Columbia University
  More Information

No publications provided

Responsible Party: Stephanie O'Malley, Professor of Psychiatry, Yale University
ClinicalTrials.gov Identifier: NCT01553136     History of Changes
Other Study ID Numbers: 1106008598
Study First Received: February 16, 2012
Last Updated: October 11, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Yale University:
alcohol-related disorders
Cholinergic Drugs
varenicline
Chantix

Additional relevant MeSH terms:
Alcohol Drinking
Alcoholism
Smoking
Drinking Behavior
Alcohol-Related Disorders
Substance-Related Disorders
Mental Disorders
Habits
Varenicline
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 22, 2013